Agreement - October 12, 2020
Inficure Bio enters new US agreement
Inficure Bio has signed an agreement with a publicly listed US biopharmaceutical company that develops drugs for several chronic and life-threatening diseases. “We will now begin testing the effects of their drug substances in our model. The company is world-leading in drug development, so this recognition is significant for us,” says Inficure Bio’s CEO, Sofia […]
Agreement - October 6, 2020
Oasmia’s partner Elevar Therapeutics signs agreement with Taiba
Oasmia Pharmaceutical announces that Elevar Therapeutics and Taiba Middle East FZ LLC have entered into an exclusive agreement under which Taiba will commercialize and distribute Apealea (micellar paclitaxel) in certain countries throughout the Middle East and North African (MENA) region. Under the terms of the agreement, Taiba will also be responsible for managing named-patient requests […]
Agreement - October 5, 2020
Alvotech extends partnership with DKSH
Alvotech and DKSH have announced an expansion of their strategic partnership to commercialize six new biosimilar product candidates for the Asian markets. The initial pipeline contains biosimilar candidates addressing multiple therapeutic areas. “We have been delighted to work with DKSH since our initial partnership began earlier this year. The partnership is designed to accelerate improved […]
Agreement - October 1, 2020
Vaccibody enters agreement with Genentech and accelerates R&D programs
Vaccibody has announced that it has entered into an exclusive worldwide license and collaboration agreement with Genentech, a member of the Roche Group, for the development and commercialization of DNA-based individualized neoantigen vaccines for the treatment of cancers. Vaccibody will conduct development through the end of Phase 1b and Genentech will be responsible for development […]
Agreement - September 17, 2020
Capitainer signs distribution deal with Speciality Diagnostix
Capitainer has signed a distribution deal with Speciality Diagnostix for Europe and Australia/New Zealand. The deal comes amid increasing interest driven by COVID-19 in Capitainer’s highly accurate qDBS dried blood spot sampling system. “Specialty Diagnostix is an ideal partner for us. They are dedicated to the marketing and distribution of novel, laboratory based assays and […]
Agreement - September 10, 2020
OnDosis enters strategic partnership
Tiefenbacher Group and OnDosis have announced the signing of a co-development agreement for multiple products in the upcoming years. The agreement covers future potential collaboration of products within five disease areas, where individualized dosing, improved patient engagement and patient safety are important to improve outcomes, they state. The first project within ADHD is already initiated […]
